therapeutic drug monitoring relates concentrations of drug in blood to response blood concentrations...
TRANSCRIPT
![Page 1: Therapeutic Drug Monitoring Relates concentrations of drug in blood to response Blood concentrations surrogate for the concentration at the site of action](https://reader036.vdocuments.mx/reader036/viewer/2022082517/56649e625503460f94b5e297/html5/thumbnails/1.jpg)
Therapeutic Drug Monitoring• Relates concentrations of drug in blood to response• Blood concentrations surrogate for the concentration at the
site of action• Has been established on the principle that the concentration
correlates better than the dose with the drug effect• Is important when
– the dose cannot be titrated against response eg INR, cholesterol
– the drug is being used to prevent infrequent occurrences - eg epilepsy
![Page 2: Therapeutic Drug Monitoring Relates concentrations of drug in blood to response Blood concentrations surrogate for the concentration at the site of action](https://reader036.vdocuments.mx/reader036/viewer/2022082517/56649e625503460f94b5e297/html5/thumbnails/2.jpg)
Conditions that must be met• Blood concentrations can be accurately reliably and
economically measured
• There is sufficient inter-individual variation in drug handling to warrant individualisation of dose
• There is a clear relationship between concentration and beneficial and/or adverse effects, particularly if there is a narrow therapeutic index
• The effects are due to the parent drug and not its metabolites
![Page 3: Therapeutic Drug Monitoring Relates concentrations of drug in blood to response Blood concentrations surrogate for the concentration at the site of action](https://reader036.vdocuments.mx/reader036/viewer/2022082517/56649e625503460f94b5e297/html5/thumbnails/3.jpg)
Purpose of TDM• To confirm ‘effective’ concentrations
• To investigate unexpected lack of efficacy
• To check compliance
• To avoid or anticipate toxic concentrations
• Before increasing to unusually large doses
• Limited role in toxicology - drug screen
![Page 4: Therapeutic Drug Monitoring Relates concentrations of drug in blood to response Blood concentrations surrogate for the concentration at the site of action](https://reader036.vdocuments.mx/reader036/viewer/2022082517/56649e625503460f94b5e297/html5/thumbnails/4.jpg)
Pharmacokinetic Considerations
• Is the aim to provide constant concentrations? - eg anticonvulsants
• Is the aim to achieve transient high concentrations without toxicity? - eg gentamicin
• Are drug concentrations likely to vary greatly between individuals on the same dose? - eg phenytoin
• Remember it takes around 5 half-lives to reach steady state
![Page 5: Therapeutic Drug Monitoring Relates concentrations of drug in blood to response Blood concentrations surrogate for the concentration at the site of action](https://reader036.vdocuments.mx/reader036/viewer/2022082517/56649e625503460f94b5e297/html5/thumbnails/5.jpg)
Practical considerations• Can the lab actually measure the drug?• What sample is needed?• What is the right timing?• Is there an accepted ‘therapeutic range’
– MEC - threshold concentration above which efficacy is expected in most patients with the disorder
– MTC - upper concentration above which the rate and severity of adverse effects become unacceptable
![Page 6: Therapeutic Drug Monitoring Relates concentrations of drug in blood to response Blood concentrations surrogate for the concentration at the site of action](https://reader036.vdocuments.mx/reader036/viewer/2022082517/56649e625503460f94b5e297/html5/thumbnails/6.jpg)
Methodological Difficulties in establishing ‘Therapeutic Range’
• Good data relating concentration to effect are seldom available
• Ideally it would require trials where participants were randomised to different plasma concentrations with follow-up and accurate and unbiased measurement of the outcomes
• See diagram of therapeutic range
![Page 7: Therapeutic Drug Monitoring Relates concentrations of drug in blood to response Blood concentrations surrogate for the concentration at the site of action](https://reader036.vdocuments.mx/reader036/viewer/2022082517/56649e625503460f94b5e297/html5/thumbnails/7.jpg)
TDM - examples• Lithium - used for bipolar disorder• Toxic - neurological, cardiac, renal• Narrow therapeutic range:
– 0.8 - 1.2 mmol/L acutely– 0.5 - 0.75 mmol/L for maintenance– Chronic concentrations of 3.0 are potentially lethal
• Renal clearance of Li can be affected by diuretics and NSAIDs
![Page 8: Therapeutic Drug Monitoring Relates concentrations of drug in blood to response Blood concentrations surrogate for the concentration at the site of action](https://reader036.vdocuments.mx/reader036/viewer/2022082517/56649e625503460f94b5e297/html5/thumbnails/8.jpg)
Anticonvulsants
• Variable dose dependant kinetics• Most metabolised through cytochrome P450 system• Concentration-related CNS toxicity can be partly avoided by
TDM• However severe skin rashes, liver and marrow toxicity cannot
be predicted or avoided• With phenytoin small dose increases can produce
disproportionate rises in blood levels and toxicity• Sometimes free (unbound) concentrations need to be measured -
eg hypoalbuminaemia, pregnancy
![Page 9: Therapeutic Drug Monitoring Relates concentrations of drug in blood to response Blood concentrations surrogate for the concentration at the site of action](https://reader036.vdocuments.mx/reader036/viewer/2022082517/56649e625503460f94b5e297/html5/thumbnails/9.jpg)
Digoxin• Has variable bioavailability• Has variable clearance (by kidney) - remember the elderly• Drug interactions are fairly common• Relationship between concentration and effect is not constant -
concentrations soon after dosing are difficult to interpret. Range is approx 1 to 2 nmol/L
• Patients may become more ‘sensitive’ to a given concentration - eg hypokalalaemia, hypothyroidism
• In atrial fibrillation titrate against the ventricular rate• Concentrations should be measure at least 6-8 hours after the last dose
![Page 10: Therapeutic Drug Monitoring Relates concentrations of drug in blood to response Blood concentrations surrogate for the concentration at the site of action](https://reader036.vdocuments.mx/reader036/viewer/2022082517/56649e625503460f94b5e297/html5/thumbnails/10.jpg)
Cyclosporin
• Used as immunosuppressant in transplant rejection
• Low therapeutic index and toxicity (kidney) is severe
• Interactions are common - eg calcium channel antagonists
• Plasma range 50-300 mg/L
![Page 11: Therapeutic Drug Monitoring Relates concentrations of drug in blood to response Blood concentrations surrogate for the concentration at the site of action](https://reader036.vdocuments.mx/reader036/viewer/2022082517/56649e625503460f94b5e297/html5/thumbnails/11.jpg)
Theophylline
• Declining use in asthma
• Very narrow therapeutic index: 55 - 110 umol/L (should be lower)
• At the high end toxicity is common
• Toxicity is severe - GI, neuro, cardiac
• Interactions are common - erythromycin, cyclosporin, cimetidine, smoking
![Page 12: Therapeutic Drug Monitoring Relates concentrations of drug in blood to response Blood concentrations surrogate for the concentration at the site of action](https://reader036.vdocuments.mx/reader036/viewer/2022082517/56649e625503460f94b5e297/html5/thumbnails/12.jpg)
Gentamicin
• Practice is changing - trend to once/daily dosing
• Toxicity relates to trough concentrations, particularly with prolonged therapy
• Desirable range:– peak 6 - 10 mg/L– trough 1-2 mg/L